FierceBiotech2d
NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space
NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), ...
Hosted on MSN2d
Sonnet BioTherapeutics secures US patent covering two drug candidates
The patent, titled ‘Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same’ was issued by the US Patent and Trademark Office. The drug candidates comprise modified versions of recombinant ...
Targeted Oncology2d
Emerging TRK Inhibitors Are Explored Across Cancer Settings
Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...
Nature6d
Detection of protein-protein interactions using the GST fusion protein pull-down technique
Because the aim of the experiment is to compare GST with a GST fusion protein, it is necessary to prepare enough precleared lysate for each reaction. Efficient mixing of reagents is the key to ...
Nature2y
Fusion Antibodies: quality by design
And, to avoid structural liabilities, Fusion Antibodies utilizes state-of-the-art three-dimensional (3D) protein structural modeling tools, rather than relying on guesswork for epitope prediction.
Business Wire18d
Celltheon Launches Revolutionary OmniCHO™ Transient Expression Kit
The kit's versatility is demonstrated by its ability to express both easy and difficult-to-express proteins, including challenging fusion proteins, antigens, and bispecifics, making it a valuable ...